跳至主要内容
临床试验/NCT00326183
NCT00326183已完成4 期

An Open, Multicenter Study of the Safety and Tolerability of VAQTA(TM) and ProQuad(TM) in Healthy Children 12 to 23 Months of Age

Merck Sharp & Dohme LLC0 个研究点目标入组 1,800 人开始时间: 2007年3月26日最近更新:
适应症
干预措施

试验速览

阶段
4 期
状态
已完成
入组人数
1,800
主要终点
Participants With 1 or More Injection-Site Adverse Experiences

研究概览

简要总结

Two doses each of Hepatitis A Vaccine, Inactivated and Measles, Mumps, Rubella and Varicella [Oka/Merck] Virus Vaccine Live will be given concomitantly or non-concomitantly. Safety data will be collected following each vaccination.

研究设计

研究类型
Interventional
分配方式
Randomized
干预模型
Parallel
主要目的
Prevention
盲法
None

入排标准

年龄范围
12 Months 至 17 Months(Child)
性别
All
接受健康志愿者

入选标准

  • Negative clinical history of hepatitis A, measles, mumps, rubella, varicella (chickenpox), and/or zoster
  • No other vaccinations scheduled to be administered at the time of the first or second doses of VAQTA(TM) and ProQuad(TM)

排除标准

  • Previously vaccinated with any hepatitis A vaccine, measles, mumps, rubella, and/or varicella vaccine either alone or in any combination
  • History of allergy to any vaccine component
  • History of seizure disorder
  • Immunosuppressed including congenial and acquired conditions and immunosuppressive therapy
  • Known severe thrombocytopenia or any other coagulation disorder that would contraindicate intramuscular injections
  • Recent (<72 hours) febrile illness (>100.3 degrees F [>37.9 degrees C] oral equivalent) prior to study vaccination.

研究组 & 干预措施

1

Active Comparator

Arm 1: vaccine

干预措施: VAQTA® (Biological)

2

Active Comparator

Arm 2: Active comparator

干预措施: VAQTA® (Biological)

2

Active Comparator

Arm 2: Active comparator

干预措施: ProQuad (Biological)

结局指标

主要结局

Participants With 1 or More Injection-Site Adverse Experiences

时间窗: Days 1 to 14 after any vaccination

Participants With Mumps-Like Symptoms After First Vaccination

时间窗: Days 1 to 28 After First Vaccination

Participants With Varicella/Zoster-Like Rash After First Vaccination

时间窗: Days 1 to 28 After First Vaccination

Participants With Elevated Temperature (>=102.2F/39.0C)

时间窗: Days 1 to 5 After Any Vaccination

Participants With Measles-Like Rash After First Vaccination

时间窗: Days 1 to 28 After First Vaccination

Participants With Rubella-Like Rash After First Vaccination

时间窗: Days 1 to 28 After First Vaccination

Participants With Rubella-Like Rash After Second Vaccination

时间窗: Days 1 to 28 After Second Vaccination

Participants With Mumps-Like Symptoms After Second Vaccination

时间窗: Days 1 to 28 After Second Vaccination

Participants With Varicella/Zoster-Like Rash After Second Vaccination

时间窗: Days 1 to 28 After Second Vaccination

Participants With 1 or More Serious Vaccine-Related Adverse Experiences

时间窗: Days 1 to 14 after any vaccination

Participants With Measles-Like Rash After Second Vaccination

时间窗: Days 1 to 28 After Second Vaccination

次要结局

  • Participants With 1 or More Systemic Adverse Experiences(Days 1 to 14 After Any Vaccination)

研究者

申办方类型
Industry
责任方
Sponsor

相似试验